LumiThera
Yang Yigang is a Board Member of LumiThera and the Founding Partner and CEO of WaterStone Capital Limited. Mr. Yang also serves on the board of directors of Robotic Vision Technology Inc. and Seattle Gummy Company, and previously served on the board of directors of Buderim Group Limited, an Australian public company. Prior to founding WaterStone, he was the CEO of COFCO Agricultural Industrial Investment Fund Management Co., Ltd. In early 2011, he founded Danmeng Contemporary Arts Investment Co., Ltd., and acted as its Chairman of the Board. In 2009, Mr. Yang was the President of Tianjin Yanshan Capital Management Co., Ltd., where he established the first Chinese Leasing Fund. He also served on the board of directors of Tianjin Bohai Leasing Co., Ltd., a Chinese public company. From 1994 to 2009, Mr. Yang worked in New York as Managing Director for Asia Capital Group, Managing Director for Capital Market Engineering and Trade LLC, and Vice President for Credit Suisse First Boston. Prior to transferring from Credit Suisse China to Credit Suisse First Boston in New York, Mr. Yang was the Chief Credit Officer at Credit Suisse Beijing Representative Office. Mr. Yang is a Member of the Investment Adviser Group of the F50, a Silicon Valley Investment Fund, Judge of the National Technology Competition hosted by the Ministry of Science and Technology of China, and Chief investment consultant of The Inner Mongolian Prairie Ecology Industry Investment Co., Ltd. Mr. Yang received his bachelor degree of Finance from Capital University of Economics and Business in Beijing.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.